Table 3 Association between the GSTM1 and GSTT1 polymorphisms and objective response rate, median survival time, median time to progression and median progression-free survival of platinum-based chemotherapy in NSCLC patients.
GSTM1 | |||||||
|---|---|---|---|---|---|---|---|
Author | Year | ORR (Good + Poor) | MST/HR | PFS/HR | |||
Present | Null | Present | Null | Present | Null | ||
Jia W. et al. | 2016 | 151 (33 + 118) | 93 (32 + 61) | Reference | 1.88 (1.01–3.47) | ||
Chen J.B. et al. | 2016 | Reference | 0.82 (0.49–1.36) | Reference | 0.78 (0.45–1.36) | ||
Xiao H.L. et al. | 2016 | 15.73 | 18.55 | ||||
163 (80 + 83) | 99 (63 + 36) | Reference | 0.40 (0.23–0.69) | ||||
Liu K. et al. | 2015 | 35.16 ± 1.72 | 35.19 ± 2.16 | ||||
155 (105 + 50) | 107 (66 + 41) | Reference | 0.85 (0.50–1.45) | ||||
Wu G. et al. | 2015 | 168 (68 + 100) | 114 (55 + 59) | Reference | 1.24 (0.74–2.11) | ||
Joerger M. et al. | 2012 | 10.2 (7.3–11.5) | 10.2 (8.2–15.7) | 6.3 (4.9–7.6) | 5.6 (4.5–6.8) | ||
80 (20 + 60) | 57 (22 + 35) | Reference | 1.13 (0.77–1.64) | Reference | 0.97 (0.69–1.38) | ||
Ada A.O. et al. | 2010 | Reference | 0.91 (0.51–1.61) | ||||
Kalikaki A. et al. | 2009 | 10.2 (7.4–13.0) | 11.3 (9.1–13.6) | ||||
72 (23 + 49) | 42 (13 + 29) | Reference | 1.2 (0.79–1.96) | ||||
Li Q.Y. et al. | 2014 | 45 (13 + 32) | 44 (13 + 31) | ||||
Mao Y. et al. | 2007 | 31 (10 + 21) | 28 (12 + 16) | ||||
Sweeney C. et al. | 2003 | Reference | 0.96–1.94 | ||||
Gonlugur U. et al. | 2006 | 9.8 ± 1.1 | 11.7 ± 1.7 | ||||
Sreeja L. et al. | 2008 | 31 | 16 | ||||
Reference | 1.2 (0.684–2.373) | ||||||
Ruano-Ravina A. et al. | 2014 | 9.4 (8.2–10.6) | 8.7 (6.0–11.4) | ||||
Reference | 1.18 (0.72–1.91) | ||||||
Li W. et al. | 2012 | 22 (8 + 14) | 36 (25 + 11) | Reference | 1.07 (0.70, 1.63) | ||
Li W. et al. | 2008 | 57 (28 + 29) | 84 (53 + 21) | ||||
Jia W. et al. | 2016 | 111 (28 + 83) | 133 (37 + 96) | Reference | 1.14 (0.62–2.11) | ||
Chen J.B. et al. | 2016 | Reference | 0.81 (0.49–1.34) | Reference | 0.67 (0.39–1.17) | ||
Xiao H.L. et al. | 2016 | 16.76 | 17.29 | ||||
145 (77 + 68) | 117 (66 + 51) | Reference | 0.84 (0.49–1.43) | ||||
Liu K. et al. | 2015 | 34.81 ± 1.83 | 35.58 ± 2.00 | ||||
141 (95 + 46) | 121 (76 + 45) | Reference | 0.88 (0.52–1.49) | ||||
Wu G. et al. | 2015 | 161 (69 + 92) | 121 (54 + 67) | Reference | 0.78 (0.47–1.31) | ||
Ada A.O. et al. | 2010 | Reference | 1.18 (0.61–2.26) | ||||
Kalikaki A. et al. | 2009 | 11.3 (9.1–13.6) | 4.3 (1.0–7.5) | ||||
106 (33 + 73) | 6 (2 + 4) | Reference | 1.2 (0.43–3.36) | ||||
Sweeney C. et al. | 2003 | Reference | 0.80–2.03 | ||||
Gonlugur U. et al. | 2006 | 12.0 ± 1.6 | 8.9 ± 1.0 | ||||
Sreeja L. et al. | 2008 | 23 | 14 | ||||
Reference | 2.1 (1.158–4.116) | ||||||
Ruano-Ravina A. et al. | 2014 | 9.8 (8.0–11.5) | 6.590.3–12.7) | ||||
Reference | 1.48 (0.84–2.60) | ||||||
